Developing science,
delivering therapies

4d

Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach
developing-science

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do
delivering-therapies

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more

News

4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of Live Biotherapeutics, today announced that data from the completed Phase Ib clinical study of Thetanix® for the treatment of Crohn’s disease will be presented on 18 May in a poster session at the 2019 Digestive Disease Week meeting in San Diego.
4D’s Research and Development team is giving a poster presentation on preclinical data from the Company’s lead Parkinson’s disease candidates
4D pharma will present preclinical data on its neurodegenerative disorders programme targeting Parkinson’s disease at two healthcare conferences

BACK TO TOP